Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Merck & Co., Inc.NYSE: MRK

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $1.58B rose 41.5% year over year, behind the +45.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.7% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Depreciation & amortization amounted to 9.0% of revenue in FY2025, up 2.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +41.5% toward the trailing-twelve-month pace of +45.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.58B+4.7% QoQ
Last fiscal yearDec 2025
$5.84B+29.8% YoY
LTMJun 2026
$6.72B+45.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.5%——
1 year+29.8%——
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
5.84B USD
Year-over-year change
+29.8%
4-year CAGR
+16.1%

Depreciation & Amortization vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.9% is the highest of 10, against a peer median of -0.4%.
  • Depreciation & amortization amounts to 10.1% of revenue for MRK, versus a peer median of 10.3%.
MRK Competitors
Depreciation & Amortization for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$8.09B USD+9.5%+2.5%8.1%
ABBVAbbVie Inc.LTM Jun 2026$7.87B USD-4.8%-1.3%12.2%
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
SNYSanofiLTM Jun 2026€5.88B EUR+22.9%+22.2%12.0%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
GILDGilead Sciences, Inc.LTM Jun 2026$2.76B USD-0.4%+9.5%9.1%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B USD+10.9%+9.5%2.6%
Peer median (excluding MRK) —-0.4%+9.2%10.3%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.36B14.53B365M17.13B18.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
Deferred Income Tax187M(1.57B)(1.9B)(1.25B)(1.67B)
Stock-Based Compensation479M541M645M761M0
Change in Working Capital(3.84B)(2.78B)(2.21B)(3.67B)(6.98B)
Accounts Receivables(2.03B)(644M)(1.15B)(244M)(1.09B)
Inventory(674M)(161M)(816M)(835M)(1.18B)
Accounts Payables405M(289M)(380M)182M110M
Other Working Capital(1.54B)(1.69B)139M(2.77B)(4.82B)
Other Non-Cash Items1.71B4.47B12.23B3.99B1.03B
Operating Cash Flow14.11B19.1B13.01B21.47B16.47B
Capital Expenditures(4.45B)(4.39B)(3.86B)(3.37B)(4.11B)
Acquisitions (Net)(12.91B)(121M)(12.03B)(4.09B)(10.04B)
Purchases of Investments(1M)(1.2B)(955M)(519M)(1.21B)
Sales of Investments1.03B721M1.66B377M1.68B
Other Investing Activities(225M)32M1.11B(127M)(58M)
Investing Cash Flow(16.56B)(4.96B)(14.08B)(7.73B)(13.74B)
Debt Repayment1.63B(2.25B)4.18B2.31B11.38B
Common Stock Issued0384M0092M
Common Stock Repurchased(840M)0(1.35B)(1.31B)(5.08B)
Dividends Paid(6.61B)(7.01B)(7.45B)(7.84B)(8.18B)
Other Financing Activities8.41B(240M)(203M)(195M)(131M)
Financing Cash Flow2.59B(9.12B)(4.81B)(7.03B)(1.92B)
Effect of Forex Changes(133M)(410M)23M(293M)563M
Net Change in Cash14M4.61B(5.86B)6.41B1.37B
Free Cash Flow9.66B14.71B9.14B18.1B12.36B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.